Clinical Trials Logo
  1. Home
  2. Alzheimer's Disease (AD)
  3. NCT02832921

Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk

Alzheimer's Disease (AD) Clinical Trial

Official title:
Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk

Clinical Trial Summary

The primary objective of this program is to apply a virtual reality (VR) cognitive-motor intervention (compared to active and passive control groups) to delay or slow cognitive decline of middle-aged adults who have a family history of Alzheimer's disease (AD) and thus are at particularly high risk of developing the disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02832921
Study type Interventional
Source Sheba Medical Center
Contact Glen M Doniger, PhD
Email Glen.Doniger@sheba.health.gov.il
Status Recruiting
Phase N/A
Start date July 2016
Completion date August 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT02593318 - Trial of Oxaloacetate in Alzheimer's Disease (TOAD) Phase 1
Completed NCT02681172 - Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Phase 4
Completed NCT02264899 - MEMENTO-VAScular COmponents of Dementia N/A
Completed NCT02531360 - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Phase 0
Recruiting NCT04570761 - Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study N/A
Not yet recruiting NCT05592678 - δ in Dementia Clinical Trials Phase 2/Phase 3
Not yet recruiting NCT05558709 - Social-cognitive Functioning: Validation of a New Neuropsychological Test N/A
Recruiting NCT05059158 - Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Completed NCT02370524 - Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease Phase 1
Completed NCT01780519 - The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms Phase 1
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Completed NCT03802162 - A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 Phase 1
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Recruiting NCT05291234 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease Phase 2
Active, not recruiting NCT05771428 - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease Phase 2
Recruiting NCT06114745 - A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Phase 1